Clinical Trials › NCT04578639
Active, Not RecruitingPhase 3
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
Sponsored by Haukeland University Hospital
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 214
Target enrollment
Nov 2020
Start date
Sep 2025
Expected completion
Interventions / Treatments
RituximabOcrelizumab
Conditions studied
Relapsing Remitting Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.